Equities research analysts forecast that Atara Biotherapeutics Inc (NASDAQ:ATRA) will announce ($1.15) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings, with the highest EPS estimate coming in at ($1.06) and the lowest estimate coming in at ($1.23). Atara Biotherapeutics posted earnings of ($0.63) per share in the same quarter last year, which would indicate a negative year over year growth rate of 82.5%. The firm is scheduled to issue its next earnings results on Thursday, March 8th.
According to Zacks, analysts expect that Atara Biotherapeutics will report full-year earnings of ($4.00) per share for the current financial year, with EPS estimates ranging from ($4.08) to ($3.91). For the next year, analysts anticipate that the company will post earnings of ($4.62) per share, with EPS estimates ranging from ($4.97) to ($4.27). Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that that provide coverage for Atara Biotherapeutics.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.05).
Shares of Atara Biotherapeutics (NASDAQ ATRA) traded up $2.70 on Friday, hitting $37.25. The stock had a trading volume of 2,190,000 shares, compared to its average volume of 1,150,000. Atara Biotherapeutics has a 12-month low of $11.80 and a 12-month high of $37.45. The stock has a market cap of $1,140.00, a price-to-earnings ratio of -10.73 and a beta of 1.27.
In related news, CEO Isaac E. Ciechanover sold 4,400 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $13.47, for a total transaction of $59,268.00. Following the transaction, the chief executive officer now owns 737,767 shares of the company’s stock, valued at $9,937,721.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Isaac E. Ciechanover sold 22,200 shares of the company’s stock in a transaction that occurred on Friday, December 29th. The shares were sold at an average price of $18.29, for a total transaction of $406,038.00. The disclosure for this sale can be found here. Insiders have sold 244,788 shares of company stock worth $5,761,853 over the last 90 days. 16.20% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of ATRA. Dimensional Fund Advisors LP grew its holdings in Atara Biotherapeutics by 2.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock valued at $304,000 after purchasing an additional 610 shares in the last quarter. Teachers Advisors LLC boosted its holdings in shares of Atara Biotherapeutics by 2.4% during the second quarter. Teachers Advisors LLC now owns 47,156 shares of the biotechnology company’s stock worth $660,000 after purchasing an additional 1,110 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Atara Biotherapeutics by 7.2% during the second quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 1,369 shares during the period. Voya Investment Management LLC boosted its holdings in shares of Atara Biotherapeutics by 16.2% during the second quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 1,651 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Atara Biotherapeutics by 11.3% during the second quarter. Rhumbline Advisers now owns 31,373 shares of the biotechnology company’s stock worth $439,000 after purchasing an additional 3,175 shares during the period. 69.67% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/28/zacks-analysts-anticipate-atara-biotherapeutics-inc-atra-to-post-1-15-earnings-per-share.html.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.